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Sørensen BH, Nielsen D, Thorsteinsdottir UA, Hoffmann EK,
Lambert IH. Downregulation of LRRC8A protects human ovarian and
alveolar carcinoma cells against Cisplatin-induced expression of p53,
MDM2, p21Waf1/Cip1, and Caspase-9/-3 activation. Am J Physiol Cell
Physiol 310: C857–C873, 2016. First published March 16, 2016;
doi:10.1152/ajpcell.00256.2015.—The leucine-rich repeat containing 8A
(LRRC8A) protein is an essential component of the volume-sensitive
organic anion channel (VSOAC), and using pharmacological anion
channel inhibitors (NS3728, DIDS) and LRRC8A siRNA we have
investigated its role in development of Cisplatin resistance in human
ovarian (A2780) and alveolar (A549) carcinoma cells. In Cisplatin-
sensitive cells Cisplatin treatment increases p53-protein level as well as
downstream signaling, e.g., expression of p21Waf1/Cip1, Bax, Noxa,
MDM2, and activation of Caspase-9/-3. In contrast, Cisplatin-resistant
cells do not enter apoptosis, i.e., their p53 and downstream signaling are
reduced and caspase activity unaltered following Cisplatin exposure.
Reduced LRRC8A expression and VSOAC activity are previously
shown to correlate with Cisplatin resistance, and here we demonstrate
that pharmacological inhibition and transient knockdown of LRRC8A
reduce the protein level of p53, MDM2, and p21Waf1/Cip1 as well as
Caspase-9/-3 activation in Cisplatin-sensitive cells. Cisplatin resistance is
accompanied by reduction in total LRRC8A expression (A2780) or
LRRC8A expression in the plasma membrane (A549). Activation of
Caspase-3 dependent apoptosis by TNF-exposure or hyperosmotic cell
shrinkage is almost unaffected by pharmacological anion channel inhi-
bition. Our data indicate 1) that expression/activity of LRRC8A is
essential for Cisplatin-induced increase in p53 protein level and its
downstream signaling, i.e., Caspase-9/-3 activation, expression of
p21Waf1/Cip1 and MDM2; and 2) that downregulation of LRRC8A-
dependent osmolyte transporters contributes to acquirement of Cisplatin
resistance in ovarian and lung carcinoma cells. Activation of LRRC8A-
containing channels is upstream to apoptotic volume decrease as hyper-
tonic cell shrinkage induces apoptosis independent of the presence of
LRRC8A.
platinum drugs; multidrug resistance; organic anion channels; tran-
scription factors; taurine; apoptosis
UNDER PHYSIOLOGICAL and pathophysiological conditions and
following chemotherapeutic treatment, outdated/damaged cells
become eliminated by apoptosis. This cell death process is
characterized by sequential net loss of osmolytes (chloride,
potassium, amino acids), cell shrinkage [termed apoptotic vol-
ume decrease (AVD)], DNA fragmentation, cleavage/activa-
tion of executor caspases, and formation of apoptotic bodies,
which in our human body is removed by blood-circulating
macrophages (8). Platinum derivatives have for a long time
been recognized for their clinical antitumor activity and are
commonly used in chemotherapeutic treatment (3). Cisplatin
[cis-diamine dichloroplatinium (II)] was the first member of a
class of platinum-based anticancer drugs, which also includes
carboplatin and oxaliplatin. Once administrated to the patients’
blood circulation, Cisplatin accumulates in the cell cytosol/
nucleus, where an aquation reaction causes the formation of a
highly reactive aqualigand (3). Binding of platinum (II) to the
nucleobases causes the formation of DNA adducts and inter-
strand cross-links that might lead to DNA lesions and trigger
the intrinsic cell death pathway. The latter involves the ataxia
telangiectasia mutated and the RAD3-related protein kinases
(ATR/ATM) as well as the transcription factor p53, and cul-
minates in the activation of apoptosis (12, 24) and/or cell cycle
arrest (10). Human p53 is described as the “guardian of the
genome” due to its ability to control the expression of several
genes and miRNAs affecting cellular processes, e.g., prolifer-
ation, DNA repair, apoptosis, autophagy, metabolism, and
migration (40). The protein level and transcriptional activity of
p53 is under normal physiological conditions kept at low levels
by the E3 ubiquitin ligase MDM2 which binds to p53’s
transactivation domain and targets p53 toward proteasomal
degradation (4, 35). DNA damage mediated by Cisplatin treat-
ment leads to a rise in p53 protein stability through ATR/ATM-
mediated phosphorylation (35) and subsequently affects cell
fate through increased transcription of 1) the cyclin-dependent
kinase inhibitor p21, which blocks cyclin-dependent kinase 1
and 2 (CDK-1 and -2) and causes G1/S and G2/M cell cycle
arrest; and/or 2) PUMA (p53-upregulated modulator of apo-
ptosis) and Noxa (PMAIP1, phorbol-12-myristate-13-acetate-
induced protein 1), which via prevention of the interaction
between proapoptotic members of the Bcl-2 family (Bax/Bak)
and anti-apoptotic proteins stabilizes the proapoptotic Bcl-2
family proteins. The latter oligomerize to form pores in the
mitochondrial membrane and facilitate cytochrome c and
SMAC (second mitochondria-derived activator of caspases)
release from the mitochondria into the cytosol. Once released
cytochrome c promotes Caspase-9 activation on a cytosolic
scaffold protein (APAF-1, apoptotic protease activating factor
1) and SMAC concomitantly lifts the effect of the caspase
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inhibitor XIAP (X-linked inhibitor of caspases). Caspase-9
subsequently activates the effector Caspases-3, -6 and -7, i.e.,
the execution of apoptosis (8).
Despite that Cisplatin has been proven to be a highly
effective chemotherapeutic agent, cancer cells tend to develop
resistance to the drug whereupon its efficacy vanishes with
time and cancer treatment fails. Drug resistance can be an
innate property (intrinsic resistance) due to permanent genetic
changes/cell differentiation or an acquired property due to
adaptations by the tumor cells (extrinsic resistance) (24). The
mechanism of platinum(II) resistance involves direct changes
in 1) drug transport systems resulting in a reduced drug uptake
via the copper transporter 1 (CTR1) and increased drug efflux
via the copper transporting ATPases (ATP7A and ATP7B); 2)
an enhanced drug detoxification due to elevated levels of
intracellular scavengers as glutathione and/or metallothio-pro-
teins; 3) changes in DNA repair involving increased nucleotide
excision, interstrand crosslink and/or less mismatch repair; 4)
changes in the tolerance toward DNA damage; or 5) changes in
the apoptotic signal transduction pathways (12, 24, 25, 32, 46).
However, within recent years, it has been found that acquire-
ment of chemotherapeutic resistance in addition to the changes
above also implies a modulated activity of volume-sensitive
transporters/channels for ions and organic osmolytes, which
limits AVD and ultimately impairs the initiation of apoptosis
(17). Using wild-type mouse Ehrlich ascites tumor cells
(EATC-WT), Hoffmann and coworkers (37) demonstrated that
AVD is a three-step process which reflects a balance between
the activities of pro- and antiapoptotic transporters for ions and
organic osmolytes. The first phase (termed AVD1) reflects net
loss of KCl and amino acids through activation of separate,
proapoptotic channels (VRAC  volume-regulated anion
channel; VSOAC  volume-sensitive organic anion channel;
TASK-2  KCNK5  potassium channel subfamily K mem-
ber 5); The second transient phase (termed AVDT) reflects net
uptake of extracellular NaCl via antiapoptotic exchange sys-
tems (NHE1: Na/H exchanger) or cotransporters (NKCC1:
Na/K/2Cl); The third phase (termed AVD2) implies mas-
sive loss of osmolytes which reflects the inability of the
antiapoptotic systems to compensate osmolyte loss via proapo-
ptotic transporters (37). The activity of the proapoptotic chan-
nels is often seen downregulated or even absent in drug-
resistant cancer cells, e.g., human epidermoid carcinoma
KCP-4 cells, human lung epithelial A549 cells (A549/CDDP),
EATC (EATC-MDR), human leukemia cells (HL60/AR), and
human ovarian A2780 (A2780CisR) (13, 30, 33, 37, 44).
Furthermore, pharmacological inhibition by administration of
more or less specific anion-channel blockers are reported to
cause drug resistance in, e.g., human epidermoid KB-3-1,
human non-small-cell lung A549, erythroleukemia K562,
HL60 promyelocytic leukemia, and MG-63 osteosarcoma
cells, as well as EATC (5, 13, 30, 33, 37).
The volume-sensitive channels for anions and organic os-
molytes (VSOAC/VRAC) are ubiquitously expressed in mam-
malian cells (18) and in April 2014 two separate groups
independently identified members of the leucine-rich repeat
containing 8 (LRRC8) family as being essential compounds/
regulators of VRAC and VSOAC (39, 45, 49). The LRRC8
family includes five members (LRRC8A to LRRC8E), and it
has been suggested that the functional channel is formed by 6
proteins from the LRRC8 family (1) and that a shift in
stoichiometry between LRRC8 members affects channel activ-
ity/selectivity (44). In this regard, it was demonstrated that
the swelling-induced Cl conductance via VRAC is medi-
ated by LRRC8A, LRRC8C, and LRRC8E (49), whereas
swelling-induced taurine efflux via VSOAC relies on
LRRC8A and LRRC8D (36). LRRC8A has been identified
as an essential component for both VRAC and VSOAC
activities, as reduced expression of LRRC8A correlates with
a reduced ability to regulate cell volume in human ovary
(A2780), colon (HCT116), cervical (HeLa), and embryonic
kidney (HEK) cells, as well as in T-lymphocytes (39, 44, 49).
Furthermore, LRRC8A expression has been demonstrated to
correlate with the swelling-induced release of the organic
osmolyte taurine from, e.g., HeLa (39), HCT116 (49), human
ovarian A2780 cancer cells (44) and primary rat astrocytes
(20). Finally, LRRC8A is also required for ATP-induced re-
lease of glutamate and taurine from nonswollen rat astrocytes
(20). A role of LRRC8 family members in cisplatin transport is
recently reviewed by Jentsch and coworkers (22).
With respect to acquirement of Cisplatin resistance, data
from our group show that LRRC8A is markedly downregulated
in Cisplatin-resistant A2780 (A2780CisR) cancer cells com-
pared with the Cisplatin-sensitive parental A2780WT, and that
this downregulation correlates with an absent swelling-induced
taurine efflux (44). Furthermore, we found that 18 h Cisplatin
exposure resulted in a 2- to 2.5-fold increase in the LRRC8A
protein content in A2780WT, whereas its expression in
A2780CisR was unaffected (44). Recent studies performed by
Yang and coworkers (55) have indicated that Cisplatin acti-
vates a Cl current in nasopharyngeal CNE-2Z carcinoma
cells, which exhibits properties similar to VRAC (outward
rectification, ATP dependence, selectivity sequence of I 
Br  Cl  gluconate), and which could be inhibited by the
anion channel blocker tamoxifen and extracellular ATP. Stud-
ies by Planells-Cases and coworkers (36) indicate that Cispla-
tin induced taurine release and the cytotoxic effects of the
chemotherapeutic drugs Staurosporine, Cisplatin and Carbo-
platin are abolished in LRRC8A and LRRC8D knockout HEK
cells (36). In this context it is noted that osmotic cell shrinkage
previously has been shown to induce Caspase-3 activation and
apoptosis in EATC via activation of a volume sensory cell
death pathway, where p53 is phosphorylated by the protein
kinase p38 and hence protected against degradation (11, 27).
Consequently, it has been suggested that Cisplatin-induced cell
death in A2780WT cells via the intrinsic cell death pathway
involves activation of the volume sensory cell death pathway
due to activation of transporters for ions/organic osmolytes/
AVD (37) and that the reduced Cisplatin sensitivity in
A2780CisR partly reflects reduced LRRC8A expression/
AVD (44). In congruence the volume sensitive Cl conduc-
tance (VRAC) and the amino acid permeability (VSOAC)
have been shown to be reduced and the AVD1 absent in
EATC-MDR (37).
In the present work we have used the human ovarian
(A2780) and lung (A549) cancer cells and find that LRRC8A
contributes to the initial phase of apoptosis induced by geno-
toxic stress as well as the regulation of p53, MDM2, and
p21Waf1/Cip1 in Cisplatin-sensitive A2780 and A549 cells. We
find that cellular sensitivity toward Cisplatin is reinstalled in
the otherwise resistant A2780 cells following expression/rees-
tablishment of LRRC8A activity. LRRC8A downregulation,
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obtained by a reduction in either total LRRC8A protein ex-
pression (A2780) or the fraction expressed in the plasma
membrane (A549), was found to be a promoting factor for
development of resistance toward Cisplatin-induced apoptosis.
EXPERIMENTAL PROCEDURES
Inorganic solutions. Phosphate-buffered saline (PBS) contained
137 mM NaCl, 2.6 mM KCl, 6.5 mM Na2HPO4, and 1.5 mM
KH2PO4. Isotonic (A2780 cells) NaCl solution (300 mOsM) con-
tained 143 mM NaCl, 5 mM KCl, 1 mM Na2HPO4, 1 mM CaCl2, 1
mM MgSO4, and 10 mM N-2-hydroxyethyl piperazine-N=-2-ethane-
sulfonic acid (HEPES). The 320 mOsM isotonic NaCl solution (for
A549 cells) was prepared by increasing the NaCl concentration to
152.5 mM. The hypotonic NaCl solution was prepared by reducing
the NaCl concentration to 92.5 mM (200 mOsM) without changing
the concentration of the other components. pH was in all solutions
adjusted to 7.4. Leu-Lys (yeast) media contained 10% ASD-10, 2%
glucose, 0.01% CaCl2, 1% leucine and 1% lysine in ddH2O (auto-
claved before use) and added 0.5% V-200 and 8 ng/ml tetracycline.
Lyticase buffer contained 100 mM Tris-HCl, pH 8.0, 100 mM EDTA
and 2/3 LB media.
Cell culture. Wild-type (WT) and Cisplatin-resistant (CisR) hu-
mane ovarian A2780 and lung A549, as well as human embryonic
kidney (HEK-293) cells, were cultured in 75-cm2 culture flasks
(CellStar, Grenier Bio, Germany) in Roswell Park Memorial Institute
(RPMI) 1640 medium or Dulbecco’s Modified Eagle medium
(DMEM), respectively. All media were supplemented with 10% fetal
bovine serum (FBS) and 1% penicillin/streptomycin. The media for
A2780 cells were additionally supplemented with 2 mM L-glutamine.
Penicillin/streptomycin, RPMI-1640, and DMEM medium, FBS, L-
glutamine, and trypsin/EDTA were purchased from Sigma Aldrich
(St. Louis, MO). Hypertonic media were obtained by supplementation
of the growth media with 150 mM NaCl. All cell cultures were kept
at 37°C, 5% CO2, and 100% humidity. The cells were subcultured two
times a week using 0.25% trypsin/EDTA in PBS. The Cisplatin-
resistant A2780 cells (A2780CisR) were, between every third pas-
sage, treated with 1 M Cisplatin to maintain their resistance pheno-
type. Likewise, resistant A549 cells were continuously treated with
either 5 (A549CisR5) or 10 (A549CisR10) M Cisplatin once a week.
Resistant A549 cells (A549CisR5 and A549CisR10) were developed
by exposing A549WT cells to an increasing concentration (up to 5 or
10 M) of Cisplatin for a period of 6 mo. The A2780 cells were a gift
from Dr. I. Romero-Canelón (Univ. of Warwick, UK). The HEK-293
lrrc8A/ (clone E7) was a gift from Prof. Thomas J. Jentsch FMP
(Leibniz-Institut fuer Molekulare Pharmakologie) and MDC (Max-
Delbrueck-Centrum fuer Molekulare Medizin), Berlin, Germany.
Transient knock-down. Transient knock-down of A2780wt and
A549wt cells was carried out using a pool of four siRNA LRRC8A
(SMARTpool: ON-TARGETplus, GE Healthcare, Dharmacon),
which has previous been used by Voss et al. (49) and siRNA p53
(SignalSilence p53, Cell signaling). MISSION Universal Negative
Control siRNA (Sigma Aldrich) was used to create a baseline for
knock-down efficiency. Cells grown to 40–50% confluence were
transfected with LRRC8A or negative control (scramble) siRNA at a
concentration of 25 nM using DharmaFECT-1 Transfection Reagent
(Thermo Scientific). For p53 silencing A2780 cells were transfected
with 10 nM, 25 nM, or 50 nM siRNA p53 for estimation of the
minimal concentration. After 24 h incubation, the medium was re-
placed by transfection reagent-free medium, and the cells were left for
another 24 h. Knockdown efficiency was estimated by Western blot
analysis of LRRC8A and by its capability to reduce swelling-induced
taurine efflux. In the case of siRNA p53 the cisplatin (10 M, 24 h)
induced increase in the p53 protein expression was found to be
reduced to 24%, 31%, and 41% by 10 nM, 25 nM, or 50 nM siRNA
p53, respectively. A concentration of 25 nM was chosen for p53
siRNA silencing.
LRRC8A-expression vector. The LRRC8A-GFP expression vector
was generated by homologous recombination in yeast. Yeast cells
were transformed with BamHI. SalI and HindIII (Fermentas, Thermo
Fischer Scientific) digested pPAP7160 vector (14) and a LRRC8A
DNA fragment. The LRRC8A cDNA fragment was obtained by PCR
using AccuPol polymerase (VWR, Denmark), a human LRRC8A
cDNA ORF clone (RC208632, OriGene) and the following primers:
LRRC8A (forward) 5=-ATA TAA GCA GAG CTG GTT TAG TGA
ACC GTC AGA TCG GGT TGA ACC ATG ATT CCG GTG ACA
GAG CT-3=and LRRC8A (reverse) 5=-ACC CCG GTG AAC AGC
TCC TCG CCC TTG CTC ACC ATG GCC TGC TCC TTG TCA
GC-3= (Tag Copenhagen A/S, Denmark). The 5= LRRC8A PCR
product carried a 35-nucleotide sequence identical to the pPAP7160
vector upstream to the restriction enzyme digestion-site while the 3=
LRRC8A PCR product contained a 35-nucleotide sequence identical
to the 5= coding sequence of EGFP on the pPAP7160 vector. Follow-
ing transformation the yeast cells were lysed by centrifugation (3.000
rpm, 5 min), addition of 1:1 lyticase buffer and 10 l lyticase (5
unit/l in TE buffer, Sigma). Cells were incubated 1 h at 37°C with
thorough vortexing. After incubation, the cells were added to 10 l
20% SDS, mixed, and frozen (20°C). The LRRC8A-expression
vector was purified using a NucleoSpin Plasmid DNA purification kit
(Macherey-Nagel, Germany). DNA yield was amplified by transfor-
mation into E.coli (OmniMax cells), followed by NucleoBond Xtra
Maxi Plasmid DNA Purification (Macherey-Nagel, Germany). The
correct nucleotide sequence of the LRRC8A vector was confirmed by
DNA sequencing. The functionality of the LRRC8A-GFP expression
vector was verified in human embryonic kidney LRRC8A KO cells
(LRRC8A/, kindly provided by Prof. Thomas J. Jentsch) where it
was determined that LRRC8A expression (verified by Western blot,
n  4, see technique below) and maximal swelling-induced taurine
release (verified by tracer technique, n 3, see technique below) were
increased 17.5 	 7.4-fold and 7.9 	 2.1-fold, respectively, following
transfection with 0.05 ng/l LRRC8A-GFP vector and 1.2 	 0.4-fold
and 1.9 	 0.4-fold, respectively. following transfection with 0.05
ng/l empty-GFP vector.
SDS-PAGE and Western blotting. SDS-PAGE and Western blot-
ting were used to quantify changes in protein levels of LRRC8A (94
kDa), p53 (53 kDa), Bax (20 kDa), p21Waf1/Cip1 (p21CDKN1A, 21
kDa), Noxa (10 kDa), MDM2 (90 kDa), phosphor-MDM2 (Ser166),
ATM (350 kDa), phospho-ATM (Ser1981), p42/p44 (Erk1/2, 42/44
kDa), phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204), human
Caspase-9 (35, 37, and 47 kDa), and the housekeeping protein 
-actin
(42 kDa), histone H3 (17 kDa), or -tubulin (52 kDa). Protein
extraction and blotting were performed on cells grown to 80–90%
confluence in 6-cm Petri dishes or 6-well culture plates. Cells were
gently washed once in ice-cold PBS and subsequently lysed in lysis
buffer containing 1% SDS, 10% glycerol, 150 mM NaCl, 20 mM
HEPES, 1 mM EDTA, 0,5% Triton X-100, 1 mM Na3VO4 and 1%
protease inhibitor cocktail. Lysates were briefly sonicated and subse-
quently centrifuged for 5 min at 5°C and 20,000 rpm to separate the
proteins extracts from insoluble cell material. The protein content was
estimated using a Bio-Rad DC protein assay (Bio-Rad, Hercules, CA).
Lysates were diluted in ddH2O (20–40 g per loading), mixed with
NuPAGE sample buffer including dithiothreitol (DTT), and pro-
ceeded to SDS-PAGE gel electrophoresis (NuPAGE precast 10% or
4–12% Bis-tris gels in NuPAGE MOPS SDS running buffer, Invit-
rogen, Waltham, MA) in NOVEX chambers under reducing and
denaturing conditions. A benchmark protein ladder (Invitrogen) was
used to indicate the molecular weight. Following electrophoresis,
NuPAGE transfer buffer (Invitrogen) was used for protein transfer to
nitrocellulose membranes. Proper protein transfer was verified by
Ponceau-S staining. Unspecific membrane-binding were blocked by
incubation in TBST (0.01 M Tris-HCl, 0.15 M NaCl, 0.1% Tween
20, pH 7.4) containing 5% nonfat dry milk at 37°C for 1 h on a
shaking table. Membranes were incubated with primary antibodies
diluted in blocking buffer overnight at 4°C. Next, the membranes
C859LEUCINE-RICH REPEAT CONTAINING 8A AND CHEMOTHERAPEUTIC RESISTANCE
AJP-Cell Physiol • doi:10.1152/ajpcell.00256.2015 • www.ajpcell.org
 by 10.220.33.6 on January 4, 2017
http://ajpcell.physiology.org/
D
ow
nloaded from
 
were washed in TBST and subsequently incubated with secondary
antibodies for 1 h at room temperature. The monoclonal mouse
anti-human-LRRC8A (SAB1412855), anti-human-p21Waf1/Cip1
(P1484), and anti-
-actin (A1978) antibodies were used in a dilution
of 1:250 (LRRC8A and p21) and 1:1,000 (
-actin) and purchased
from Sigma-Aldrich. Noxa (no. 14766), ATM (no. 2873), phospho-
ATM (no. 13050), phosphor-MDM2 (no. 3521), Bax (no. 2772), p53
(no. 2524), Caspase-9 (no. 9502), Histone H3 (no. 9717), -Tubulin
(no. 2125), and phospho-p53 (no. 9284) antibodies were from Cell
Signaling (Danvers, MA) and used in a dilution of 1:250 (Noxa,
phosphor-MDM2, Bax, Caspase-9, Histone H3, -tubulin and phos-
phor-p53) or 1:100 (ATM, phosphor-ATM and p53), respectively.
The antibody against MDM2 (sc-965) was from Santa Cruz Biotech-
nology and used in the dilution of 1:100. The antibody against the
COOH-terminal part of the Na/K-ATPase antibody was made and
kindly donated by Prof. Per Amstrup-Pedersen (Univ. of Copenhagen,
Denmark) and used in the dilution 1:250. The secondary AP-
conjugated anti-mouse and anti-rabbit antibodies (Sigma) were both
used in a dilution of 1:5,000. Following final washes in TBST,
membranes were developed using BCIP/NBT (KPL, Gaithersburg,
MD), scanned and bands quantified using UN-SCAN-IT (Silk Scien-
tific).
Cell surface biotinylation and membrane protein isolation.
A549WT and CisR10 cells, grown to 80% confluence in four T75
flasks (each), were biotinylated, lysed and labeled proteins isolated
using Pierce Cell Surface Protein Isolation Kit (Thermo Fisher Sci-
entific) following manufacturer’s instructions. SDS-PAGE and West-
ern blotting were used to analyze the amount of LRRC8A, Na/K-
ATPase (positive plasma membrane control/loading control), and
Histone 3 (nuclear control) in both whole cell lysate and purified
samples.
Cell viability assay-MTT. Conversion of the yellow soluble tetra-
zolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT from Sigma) into a blue insoluble formazan was used to
determine cell viability after treatment of WT and resistant cells with
10 M Cisplatin for 48 h. Cells were seeded to a density of 10,000
(A2780) or 5,000 (A549) cells/200 l cell culture media per well in
96-well plates and incubated for 96 h (37°C, 5% CO2, 100% humid-
ity). Cells were after 48 h transiently transfected with 25 nM siRNA
(human LRRC8A siRNA or 2 ng/l scramble siRNA) or a vector
(either expressing LRRC8A-GFP or an empty vector only carrying the
GFP gene) using DharmaFECT-1 Transfection Reagent (Thermo
Scientific). After 24 h incubation, media were changed to normal
growth medium or medium containing 10 M Cisplatin and/or 400
M DIDS. At the end of the incubation period, 100 l was removed,
and 25 l of a MTT solution (5 mg/ml MTT in sterilized PBS) was
added to each well, and the plate was incubated in the cell culture
incubator for 3 h. Following incubation 100 l fresh-made 10 mM
HCl containing 1% SDS was added to each well and incubated
overnight in a fume hood to solubilize the colored formazan crystals.
Samples were measured at 570 nm using Wallac Envision Multilabel
plate reader (PerkinElmer). Data were represented relative to the
absorbance from the respective untreated control cells. Each experi-
ment was performed in triplicate.
Caspase-3 colorimetric protease assay. Wild-type, resistant, and
transiently transfected A2780 cells were grown to 80% confluency in
T25 culture flasks and incubated in the presence or absence of 10 M
NS3728 or 400 M DIDS in combination with 10 M Cisplatin, 20
ng/ml TNF, or 150 mM NaCl (600 mOsM) for 18 or 4.5 h. Cells
were carefully washed once in ice-cold PBS, trypsinized, and trans-
ferred to 15 ml falcon tubes with RPMI-1640 (A2780). Next, the cell
suspensions were centrifuged at 1,000 g for 5 min at room tempera-
ture, and the extracellular medium was carefully removed to collect all
cellular material including apoptotic bodies. The cell suspensions
were then washed one additional time in PBS, centrifuged as before
and cell pellet carefully collected. The cells were lysed in ice-cold
lysis buffer for 15–20 min, transferred to Eppendorf microcentrifuge
tubes, and centrifuged (5 min at 10,000 g, 4°C) to precipitate non-
soluble cell material. The supernatants were transferred to new Ep-
pendorf tubes and protein concentrations were estimated using a
Bio-Rad DC protein assay with bovine serum albumin (BSA) as a
standard. Lysates, which were not used immediately, were stored
at 80°C until use. The protein content was, before activity measure-
ments, adjusted to 4 g/l. Caspase-3 activity in cell lysates was
estimated in black 96-well plates with transparent bottom using the
ApoTarget Caspase-3/CPP32 Colorimetric assay (Invitrogen, Taas-
trup, Denmark) according to the manufacturer’s manual by measuring
protease activity toward the peptide substrate acetyl-Asp-Glu-Val-
Asp p-nitroanilide (Ac-DEVD-pNA) and estimating the p-nitroanilide
(pNA) production. Absorbance was measured at 405 nm using a
Wallac Envision Multilabel plate reader (Perkin Elmer). Experiments
were performed in duplicate.
Caspase-9 activity. The intrinsic proteolytic Caspase-9 activity was
determined by SDS-PAGE and Western Blotting (see above).
Estimation of taurine efflux. Swelling-induced taurine efflux was
estimated at room temperature on cells grown to 80% confluence in 6
well polyethylene culture plates as previously described (26). Cells
were loaded with [3H]taurine (PerkinElmer, 37,000 Bq/well) in com-
plete growth medium for 2 h (37°C, 5% CO2, 100% humidity). Before
the experiment, the growth media was removed and each well (each
representing one experiment) was washed 3 times with 1 ml isotonic
NaCl medium (300 or 320 mOsm) to remove residual extracellular
isotope and growth media. The experiment was performed at room
temperature by transferring the NaCl medium from each well to
individual scintillation vials (Snaptwist Scintillation vial, 6.5 ml,
VWR) and replacing it with fresh medium at 2-min intervals. The
experiment was run for the total of 30 min, in the absence or presence
of inhibitors, i.e., the specific VRAC/VSOAC blocker NS3728 (a gift
from NeuroSearch, Denmark) and DIDS (4,4=-diisothiocyanatostil-
bene-2,2=-disulfonate, dissolved in ddH2O, Sigma Aldrich). At time
12 min, isotonic medium was replaced by hypotonic medium (200
mOsm). At the end of the experiment, remaining intracellular isotope
was extracted by addition of 1 ml 1 M NaOH (1 h, shaking table)
followed by two additional washes with ddH2O. Each vial was added
to 3.5 ml scintillation fluid (Parkard Ultima Gold, PerkinElmer),
mixed carefully, and proceeded to 
-scintillation counting in a Perkin
Elmer scintillation counter (Waltham, MA). The total 3H activity in
the cell system was calculated as the sum of 3H activity released
during the efflux experiment and in the NaOH/water washouts. The
fractional taurine release rate constant (k, min1) was calculated from
the equation: k  [ln(X1)  ln(X2)]/(t1  t2), where X1 and X2 denote
the fraction remaining in the cell at time t1 and t2, respectively.
Statistics. All data were statistically tested (SigmaPlot version 12)
by one-way ANOVA with Fisher LSD Method as post test and/or by
Student’s t-test. In bar- and scatterplots the error bars signify standard
error of the mean (SE).
RESULTS
Several groups have recently shown that LRRC8A signifi-
cantly contributes to VRAC/VSOAC channel activity either by
being a regulatory subunit or a critical channel pore-forming
component (36, 39, 49). With respect to drug resistance, data
from our group have indicated that development of resistance
in human ovarian A2780 carcinoma cells correlates with a
reduced LRRC8A protein expression, and an inability to acti-
vate VSOAC and to volume-regulate in response to hypos-
motic cell swelling (44). Here we establish an in vitro cell-
based assay by which it is possible to investigate the direct
involvement of LRRC8A-mediated channel activity in devel-
opment of resistance against Cisplatin. For this purpose, we use
volume-sensitive release of the organic osmolyte taurine to
track VSOAC activity (28), pharmacological inhibitors, which
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are known to inactivate VRAC/VSOAC, and commercially
available siRNAs, which have previously been used to selec-
tively knock-down human LRRC8A (49). From Fig. 1A, it is
seen that acute exposure to the two anion-channel inhibitors
NS3728 and DIDS abolishes the swelling-induced taurine
efflux in ovarian A2780WT cells. Both NS3728 and DIDS
were found to reduce the maximal taurine rate constant more
than 90% compared with the untreated control cells (Fig. 1B).
These data are in accordance with what has previously been
shown for this and other cell lines (19, 44). As NS3728 and
DIDS are also known to affect the activity of, e.g., anion
channels like the Ca2-dependent Anoctamin channels (15, 23,
42), we used siRNA directed against human LRRC8A to
specifically knock-down VRAC/VSOAC channel activity. Fig-
ure 1, C and D, shows a representative Western blot from a
knock-down experiment and the corresponding quantification,
respectively. From these figures it is seen that we successfully
managed to knock-down the LRRC8A protein content to 40%
in A2780WT cells. To test the effect of LRRC8A knock-down
in A2780 cells, we determined the ability of the knock-down
cells to release taurine in response to hyposmolality (Fig. 1E).
These data likewise confirm the previous assumption that
LRRC8A significantly contributes to VRAC/VSOAC channel
activity and that the observed knock-down efficiency seen by
Western blot analysis (Fig. 1, C and D) correlates with the
reduction in swelling-induced taurine efflux (Fig. 1E).
Eighteen-hour exposure to anion- and cation-channel block-
ers increases LRRC8A protein content in wild-type A2780
cells. We have tested the effect of increasing pharmacological
channel blockage on LRRC8A protein expression. Figure 2
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Fig. 1. Impairment of swelling induced taurine release following pharmacological inhibition or transient knock-down of LRRC8A in wild-type A2780 cells.
Volume-sensitive taurine release and LRRC8A protein expression were measured in ovarian A2780WT cells by tracer technique and Western blot analysis,
respectively. A2780WT cells were loaded with [3H]taurine for 2 h, washed, and exposed to isosmotic NaCl medium (300 mOsM) for 10 min and subsequently
to hyposmotic medium (200 mOsM) for 20 min (arrow in A indicates shift to hypotonicity). Samples were taken every second minute. A: fractional rate constant
(min1) for taurine release was determined and plotted vs. time (min) under isosmotic and hyposmotic conditions in the absence (Œ) or presence of the
VRAC/VSOAC blockers NS3728 () or DIDS (). The anion blockers NS3728 and DIDS were used in the concentration of 10 M (2.5 M free) and 100
M, respectively, and present during the isotonic/hypotonic release experiment. Data represent 1 of 3 sets of experiments. B: maximal rate constant for taurine
release was determined 6 min after hyposmotic exposure as illustrated in A. Data represent the mean maximal rate constants determined from 3 sets of
experiments 	 SE. *Significantly reduced compared with control (Student’s t-test). C: efficiency of siRNA-mediated LRRC8A knock-down in A2780WT cells
was determined by Western blot analysis using control, scramble siRNA and LRRC8A siRNA transfected cells and specific monoclonal antibody raised against
human LRRC8A and 
-actin (loading control). D: LRRC8A/
-actin protein band intensity ratios were calculated from Western blots shown in C and values given
relative to control cells. Data represent mean of 4 experiments 	 SE. * and #: Significantly reduced compared with Control and Scramble siRNA, respectively
(Student’s t-test). Scramble siRNA was not significantly larger than Control (P  0.15, Student’s t-test). E: maximal rate constant for taurine release was
determined at time 6 min after hypotonic exposure in A2780WT (open bar) cells or in A2780 cells exposed to scramble siRNA (light gray bar) or siRNA directed
against human LRRC8A (dark gray bar). Data represent mean of 4 experiments 	 SE. *Significantly reduced compared with Control (Student’s t-test).
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shows that exposing A2780WT cells for 18 h to an increasing
concentration of the anion channel blockers NS3728 and DIDS
results in an increased LRRC8A protein expression, indicating
that the A2780 cells apparently compensate for an acute
reduction in LRRC8A channel activity by upregulating the
protein-expression of the channel proteins. We also find that
inhibition of K channels with clofilium increases LRRC8A
expression in A2780 cells (Fig. 2). Whether the latter effect is
related to a concomitant depolarization of the membrane po-
tential and hence a decrease in the driving force for transport of
anions through the LRRC8A channel complex was not inves-
tigated further.
Administration of anion- and cation-channel blockers abol-
ishes Cisplatin-induced increase in p53/p21Waf1/Cip1 protein
expression in wild-type A2780 cells. It has previously been
shown that acute hyperosmotic stress leads to a biphasic
stabilization and activation of the transcription factor p53 in
mouse NIH3T3 fibroblasts, supposedly through Ser-15 phos-
phorylation of p53 by the serine/threonine kinase ATM and/or
the p38 MAP kinase (11, 27). As exposure to Cisplatin like-
wise elicits cell shrinkage under isotonic conditions, we tested
the effect of Cisplatin on p53-mediated signaling. From Figs.
3A (Western blots) and Fig. 3B (protein quantification), it is
seen that 18 h exposure to Cisplatin, similar to osmotic cell
shrinkage, leads to an increased p53 protein expression/phos-
phorylation (Ser15) as well as an enhancement of the expres-
sion of downstream elements to p53, e.g., p21Waf1/Cip1 and a
minor increase in Bax in A2780WT cells. From Fig. 3, A and
B, it is also seen that the Cisplatin-induced p53 protein expres-
sion and downstream signaling is almost absent in the corre-
sponding Cisplatin-resistant subtype A2780CisR, although a
minor, significant increase in p53 phosphorylation is observed.
As the protein expression of LRRC8A has previously been
found markedly downregulated in A2780CisR (44), we wanted
to test whether administration of the pharmacological VRAC/
VSOAC blockers NS3728 and DIDS might give rise to the
same phenotype in A2780WT cells, as observed in
A2780CisR. From Fig. 3C it is seen that Cisplatin cotreatment
with either NS3728 or DIDS significantly reduces p53 and
p21Waf1/Cip1 protein level in A2780WT cells, i.e., the wild-type
A2780 cells resemble A2780CisR in the presence of the
inhibitors. Ser-15 phosphorylation of p53 was affected as well
in A2780WT by the inhibitor although not to the same extent
as observed for total p53 and p21Waf1/Cip1. This could indicate
that VRAC/VSOAC activity is not important for the phosphor-
ylation of p53, but rather regulates its expression and/or sta-
bility independently of the phosphorylation. As the activity of
VRAC/VSOAC is highly dependent on the coactivity of po-
tassium channels like TASK-2 to maintain a stable membrane
potential, we wondered if the TASK-2 channel blocker clo-
filium might also affect Cisplatin-induced p53 stabilization/
activation and downstream signaling. Supportively, we found
that clofilium also prevents the increase in p53 protein expres-
sion and hinders its induction of p21Waf1/Cip1 (Fig. 3C). These
data indicate that coactivity of anion- and cation-channels,
which leads to cell shrinkage, is necessary for Cisplatin-
induced stabilization/activation of p53 and its downstream
signaling involving increased expression of p21Waf1/Cip1.
Studies by Wang and colleagues (52) indicate that Cisplatin-
induced apoptosis requires activation of the MAP kinase sig-
naling pathway in a process involving growth receptor trans-
activation, and downstream activation of MEK1/2 and
Erk1/3 in HeLa and A549 cells. Woessman and coworkers
(53) find that Ras-mediated activation of ERK by cisplatin
induces cell death independently of p53 in osteosarcoma and
neuroblastoma cell lines. In contrast, Persons and coworkers
(34) find that p53 coimmunoprecipitates with ERK1/2 and
that inhibition of ERK1/2 activation reduces Cisplatin-
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Fig. 2. Eighteen-hour exposure to anion- and cation-
channel blockers leads to increased LRRC8A protein
expression in wild-type A2780 cells. Wild-type A2780
cells were exposed to increasing concentrations of the
anion- and cation-channel blockers (NS3782, DIDS,
and Clofilium) for 18 h. A: lysates were taken and used
for Western blot analysis using a monoclonal antibody
raised against human LRRC8A and 
-actin (loading
control). B: LRRC8A/
-actin protein band intensity
ratios were calculated from Western blots shown in A
and values given relative to control cells. Data repre-
sent mean of 7 sets of experiments 	 SE. # and *:
Significantly increased compared with Control without
inhibitor when tested by ANOVA, Fisher LSD method
and Student’s t-test, respectively.
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mediated p53-phoshorylation (Ser15), i.e., Cisplatin induced
ERK1/2 signaling is an upstream event to p53 activation in
A2780 cells. Figure 4 shows that exposure to 20 M
Cisplatin for 14 h indeed leads to an increased phosphory-
lation of Erk2 in both A2780WT and A2780CisR. Total
Erk1 and Erk2 protein expression is unaffected by Cisplatin.
Cotreatment with the anion channel blocker DIDS com-
pletely abolished the Erk2 phosphorylation in A2780WT,
indicating that VSOAC/VRAC might also be a regulator of
the MAP kinase signaling pathway. We find that only
treatment with Cisplatin concentrations above 20 M Cis-
platin, in correspondence with Wang and coworkers find-
ings, leads to an increased phosphorylation of Erk1/2. This
indicates that Cisplatin-induced activation of Erk1/2 may be
less important, as the plasma Cisplatin concentration in
cancer patients, treated with 100 mg Cisplatin/m2, stabilizes
at 10 M (16). The involvement of Erk1/2 was therefore not
investigated further.
Cotreatment with anion-channel blockers and transient
knock-down of LRRC8A eliminate Cisplatin-induced, but not
TNF and hyperosmotic-induced Caspase-3 activation in
wild-type A2780 cells. An increase in Caspase-3 activity has
previously been used as an indicator of apoptotic progress, and
it is commonly known that p53 activity is an upstream event
for cleavage and activation of Caspase-3 in response to several
types of cellular stress, e.g., Cisplatin-induced genome toxicity
and hyperosmolarity (11, 27). From Fig. 5A it is seen that 10
M Cisplatin (18 h) induces a 2-fold increase in Caspase-3
activity in A2780WT, whereas Caspase-3 activity in
A2780CisR is unaffected by Cisplatin. Furthermore, we find
that VRAC/VSOAC inhibition with NS3728/DIDS (Fig. 5A)
reduces the Cisplatin-induced Caspase-3 activation in
A2780WT to the level we observed in A2780CisR. Transient
knock-down of LRRC8A (Fig. 5B) abolishes the Cisplatin-
induced Caspase-3 activation (Fig. 5B). These data illustrate
that downregulation of LRRC8A in A2780WT results in re-
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Fig. 3. Administration of anion- and cation-channel blockers reduces Cisplatin-induced expression of p53 and p21Waf1/Cip1 in wild-type A2780 cells (A2780WT)
to the same level as observed in Cisplatin-resistant A2780 cells (A2780CisR). Whole cell protein lysates for Western blot analysis were obtained from A2780WT
and A2780CisR cells exposed to 10 M Cisplatin for 18 h in combination with the anion/amino acid channel blockers NS3728 (100 M)/DIDS (400 M) or
the cation-channel (TASK-2) blocker clofilium (25 M). Only A2780WT cells were exposed to channel blockers. Protein expression of LRRC8A, p53, p-p53
(Ser15), p21, and Bax was determined using specific antibodies (see EXPERIMENTAL PROCEDURES). 
-Actin was used as loading control. A: representative Western
blot. B: p53, pp53, p21, and Bax protein expression relative to 
-actin in A2780WT and A2780CisR (open bars) control cells and following Cisplatin exposure
(black bars). Data represent 4–9 individual sets of experiments where ratios are given relative to the untreated WT cells	 SE. * and #: Expression is significantly
increased in Cisplatin-treated cell compared with control cells and significantly reduced in Cisplatin-treated A2780CisR cells compared with Cisplatin-treated
A2780WT cells, respectively (ANOVA, Fisher LSD method). C: graph represents the relative effect of Cisplatin (Cisplatin-treated/respective untreated control)
on LRRC8A, p53, p-p53, and p21 protein expression in A2780WT, A2780CisR (CisR), and A2780WT cells cotreated with the anion- and cation-channel
blockers. Data represent mean of 4–9 individual experiments 	 SE. *Significantly reduced effect of Cisplatin compared with A2780WT (ANOVA, Fisher LSD
method).
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sistance against Cisplatin-induced apoptosis. To identify at
which signaling-level VRAC/VSOAC is involved in the apo-
ptotic pathway, we investigated the involvement of VRAC/
VSOAC channel activity on the apoptotic pathway initiated by
other types of apoptotic stimulation, e.g., by exposure to TNF
(extrinsic pathway) and hyperosmolality (volume-sensory
pathway). From Fig. 5C it is seen that TNF induces a 3- to
3.5-fold and 4.5-fold increase in Caspase-3 activity in
A2780WT and A2780CisR cells, respectively. These data
thereby confirm our previous results that A2780CisR still
enters apoptosis following TNF exposure (44). When testing
the TNF effect during anion-channel blockage, we found only
a slight tendency for NS3728 and DIDS to reduce TNF-
induced apoptosis, which is taken to indicate that VRAC/
VSOAC activity is not necessary for death-receptor stimulated
Caspase-3 activation in A2780 cells. With respect to Caspase-3
activation induced by hyperosmolality, we found that cell
shrinkage per se leads to a 6-fold increase in Caspase-3
activity, and that neither NS3728 nor DIDS had any effect on
the caspase stimulation (Fig. 5D). Hence, hyperosmotic
Caspase-3 activation happens independently of VRAC/
VSOAC activities and most probably directly as a consequence
of the shrinkage of the cells.
Pharmacological inhibition of VSOAC activity protects
A2780WT cells against Cisplatin-induced reduction in cell
viability, whereas an artificial expression of LRRC8A in
A2780CisR restores Cisplatin-sensitivity. To verify the cellular
effect of LRRC8A and pharmacological blockage of VSOAC
on Cisplatin cytotoxicity, we performed a MTT cell viability
assay. From Fig. 6, A and B, it is seen that treatment of A2780
cells with 10 M Cisplatin for 48 h reduces cell viability to
50% in A2780WT cells, whereas an equivalent treatment of
A2780CisR only reduces cell viability to 80%. Cotreatment
with DIDS increases cell viability after Cisplatin treatment in
both A2780WT and A2780CisR (Fig. 6A), confirming that the
cytotoxic effects of Cisplatin are highly dependent on VSOAC
activity. As A2780CisR was previously shown to have a
significantly reduced LRRC8A protein expression compared
with A2780WT (44), we tested whether Cisplatin cytotoxicity
could be restored in A2780CisR by artificially increasing the
expression of LRRC8A. Figure 6B shows that expression of a
vector carrying a constitutively active promoter for a LRRC8A
gene reduces cell viability in A2780CisR following Cisplatin
treatment. Hence, LRRC8A reinstallation renders A2780CisR
sensitive to Cisplatin. It is noted that expression of the
LRRC8A vector has no effect on cell viability in A2780WT
cells as LRRC8A activity is ensured by the endogenous
LRRC8A expression. The low viability in cells treated with
Cisplatin plus vector most probably reflects the transfection
procedure.
Abrogation of prolonged cisplatin treatment restores Cis-
platin-sensitivity in A2780CisR within 3–6 wk. As develop-
ment of drug resistance is one of the main issues in chemo-
therapeutic treatment, we investigated the probability that ter-
mination of prolonged Cisplatin treatment, which is normally
used to maintain resistance in vitro, could reverse the Cispla-
tin-resistant phenotype and thereby restore Cisplatin sensitivity
in A2780CisR. We have previously shown that Cisplatin re-
sistance in A2780CisR cells correlated with an increased ac-
cumulation of taurine due to an increased taurine uptake via the
taurine transporter TauT and a concomitant reduction in vol-
ume-sensitive taurine release via VSOAC (44). Figure 7, A and
B, shows that abrogation of Cisplatin treatment of A2780CisR
for 3 and 6 wk reduces taurine uptake and increases swelling-
induced taurine release (shown as the maximal rale constant
obtained after osmotic cells swelling) to the same level as ob-
served for A2780WT. From representative Western blots (Fig.
7C) and their corresponding quantification (Fig. 7, D and E), it is
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Fig. 4. The anion-channel blocker DIDS reduces Cispla-
tin-induced Erk-2 phosphorylation in A2780 cells.
Whole cell protein lysates for Western blot analysis were
obtained from A2780WT and A2780CisR cells exposed
to 0, 10, or 20 M Cisplatin for 14 h in combination with
the anion/amino acid channel blockers DIDS (400 M).
Only A2780WT cells were exposed to DIDS. Total
Erk-1/-2 protein and phospho-Erk-1/-2 expression were
determined using specific antibodies (see EXPERIMENTAL
PROCEDURES). Histone-3 (H3) was used as loading con-
trol. A: representative Western blot. B: phospho-Erk-1
protein expression relative to total-Erk-1 (gray bars) and
phospho-Erk-2 protein expression relative to total-Erk-2
(black bars) in A2780WT, A2780WT cotreated with
DIDS, and A2780CisR control cells and following 14 h
Cisplatin exposure. Data represent 5 individual sets of
experiments, where ratios are given relative to the un-
treated WT cells 	 SE. * and § indicate that the Erk-
phosphorylation ratio is significantly increased in Cispla-
tin-treated cells when compared with the respective con-
trol cells; # indicates that the Erk-phosphorylation ratio
in cisplatin-treated A2780WT cells is significantly re-
duced by DIDS (ANOVA, Fisher LSD method).
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seen that interruption of the continued Cisplatin treatment indeed
restored 1) the LRRC8A expression, and 2) the Cisplatin-
induced expression of p53, Noxa and p21Waf1/Cip1 as well
Cisplatin sensitivity (seen as an increase in cleaved Caspase-9)
during the first 3–6 wk. These data demonstrate that cessation
of prolonged Cisplatin treatment can restore Cisplatin-induced
signaling and sensitivity in A2780 cells.
Development of Cisplatin resistance in human alveolar
A549 cells involves reduced swelling-induced taurine efflux,
reduced LRRC8A expression in the plasma membrane and
abolished Caspase-9/-3 activation. As Cisplatin, Oxaliplatin,
and Carboplatin are commonly used to treat various types of
lung cancer, we wished to establish a Cisplatin-resistant variant
of the alveolar A549 adenocarcinoma cell line to test whether
development of resistance in this cell type similar to A2780
cells would involve an altered LRRC8A expression, VRAC/
VSOAC activity and intracellular signaling along the p53-
dependent cascade. Two Cisplatin-resistant A549 cell lines
(denoted A549CisR5 and A549CisR10) were developed in our
group by exposing A549WT cells to 5 M or 10 M Cisplatin
for 6 mo. To verify that A549CisR5 and A549CisR10 cell lines
are actually resistant to Cisplatin we used the Caspase-3
activity assay and cleavage of Caspase-9, as indicators of the
apoptotic progress. Figure 8A shows that exposure of A549WT
cells to 10 and 20 M Cisplatin for 24 h results in a 3.6 and
6.8-fold increase in Caspase-3 activation, respectively. How-
ever, exposing the A549CisR5 and A549CisR10 cells to the
same concentrations of Cisplatin did not cause any Caspase-3
activation, thereby confirming their Cisplatin-resistant nature.
Furthermore, Fig. 8B shows that exposure of A549CisR10 to
10 M Cisplatin does not lead to any increase in Caspase-9
cleavage, whereas exposure of A549WT to the same treatment
results in a 4-fold increase in Caspase-9 cleavage. From Fig. 8,
C and D, it is seen that A549CisR5 and A549CisR10 show a
decreased ability to activate VSOAC and release taurine in
response to hyposmolality, i.e., the maximal rate constant in
both A549CisR5 and A549CisR10 was reduced to 50% com-
pared with the A549WT cells. To test whether VSOAC activity
in A549CisR5 and A549CisR10, similar to findings with the
Cisplatin-resistant human ovarian A2780, correlates with a
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decreased LRRC8A protein expression, we performed Western
blot analysis to compare LRRC8A protein expressions in
wild-type and resistant A549 cells. Figure 8E shows to our
surprise that the protein expression of LRRC8A is either
unaffected or even increased in the Cisplatin-resistant subtypes
compared with A549WT cells. However, similar to our find-
ings with A2780 (Fig. 6B) we find cell death in A549WT,
induced by 48 h exposure to 10 M Cisplatin, is reduced, i.e.,
cell viability increased following transient knock-down of
LRRC8A (Fig. 8F). Assuming that reduction in the LRRC8A
expression/activity results in development of Cisplatin resis-
tance, the increased LRRC8A expression in A549CisR10 cells
(Fig. 8E) could indicate that the reduced VSOAC activity in
the Cisplatin-resistant A549 cells is caused by less LRRC8A
being installed in the membrane, failing VSOAC activation, or
reduction in the coexpression of other essential VSOAC com-
ponents (e.g., LRRC8D). To measure expression of LRRC8A
in the plasma membrane we isolated biotinylated cell surface
proteins from A549WT and A549CisR10 cells and quantified
the amount of LRRC8A, Na/K-ATPase (positive plasma
membrane control/loading control), and Histone 3 (nuclear
control) in both whole cell lysate and purified samples. From
Fig. 9 it is seen that even though total LRRC8A expression in
A549CisR10 is unaltered or increased compared with
A549WT (Fig. 8E) significantly less LRRC8A is expressed in
the plasma membrane. Hence, the impaired Cisplatin-induced
Caspase-9 and -3 activation in A549CisR10 cells seems to
reflect impairment of LRRC8A protein expression in the mem-
brane and the concomitant reduction in VSOAC activation.
Intracellular trafficking of LRRC8A was not investigated fur-
ther.
Selective knock-down of LRRC8A abolishes Cisplatin-in-
duced expression of p53, MDM2 and p21Waf1/Cip1 and reduces
p53 activation in alveolar A549 cells. From Fig. 10, A–C, it is
seen that 24 h exposure to Cisplatin leads to an increased p53
protein expression and Ser-15 phosphorylation as well as an
enhancement of its downstream signaling involving expression
of p21Waf1/Cip1, MDM2, Noxa, Bax, activation of the ATM
kinase, and Caspase-9 cleavage in alveolar A549WT cells. The
Cisplatin-induced p53 protein expression and downstream sig-
naling are absent in the corresponding resistant subtype
A549CisR10, thus confirming its Cisplatin-resistant pheno-
type. It is noted that the basal-level of p21Waf1/Cip1, Noxa,
pATM and MDM2 seems higher in the resistant cells, in a way
which was unaffected by Cisplatin treatment (Fig. 10C). Sev-
eral studies indicate that an increase in the expression of
antiapoptotic proteins, c-IAP1 and survivin, contribute to che-
motherapy resistance (48, 51). Hence, this could explain why
cell lines with acquired resistance overcome an increased level
of proapoptotic proteins and proteins regulating cell cycle
progression. As we have previously shown that administration
of the pharmacological VRAC/VSOAC blockers induces Cis-
platin resistance in A2780 cells (Fig. 3, A and C), and that
LRRC8A-mediated channel activity is found downregulated or
even absent in many Cisplatin-resistant cell lines including
A2780CisR, A549CisR and EATC-MDR (see Introduction),
we wondered whether knock-down of LRRC8A might directly
cause resistance in A549 cells. From Fig. 10A (Western blot)
and 10D (quantification) it is seen that transient knock-down of
LRRC8A significantly reduces p53, MDM2 and p21Waf1/Cip1
expression, as well as Caspase-9 activation (seen as reduced
cleavage) in A549WT cells. The protein expression of
LRRC8A, given as the LRRC8A/actin protein band ratio, was
in these experiments significantly reduced (P  0.05) from
1.91 	 0.43 in A549WT cells treated with scramble siRNA to
0.21	 0.09 in A549WT cells treated with LRRC8A siRNA for
48 h. The Ser-15 phosphorylation of p53 (Fig. 10D) and
Ser-166 phosphorylation of MDM2 (0.8 	 0.5 scrambled
siRNA; 1.0 	 0.6 LRRC8A siRNA; n  3; values relative to
control) were not significantly affected. Thus, similar to the
findings with anion-channel blockers in A2780 cells, this
demonstrates that LRRC8A activity is not important for the
phosphorylation of p53, but is entirely essential for Cisplatin-
induced stabilization of p53 and its downstream signaling
involving increased expression of p21Waf1/Cip1.
Cisplatin-mediated DNA damage often leads to a rise in
p53 protein stability through ATR/ATM-mediated phos-
phorylation. We have tested the possibility that LRRC8A
directly regulates Cisplatin-induced Ser1981 phosphoryla-
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tion of ATM, as the phosphorylation was found absent in
A549CisR10. From the Western blots shown in Fig. 10B it
is determined that LRRC8A knock-down does not affect
ATM protein expression (1.4 	 0.3 scrambled siRNA;
1.1 	 0.2 LRRC8A siRNA; n  3; values relative to
control) nor ATM Ser1981 phosphorylation (3.5 	 0.5
scrambled siRNA; 3.5 	 1.4 LRRC8A siRNA; n  3;
values relative to control). The absent Cisplatin-induced
ATM activation in A549CisR10 might reflect a reduced
Cisplatin uptake via, e.g., CTR1 or other resistance mech-
anisms (see Introduction), Hence, LRRC8A is most proba-
bly a downstream element to or completely independent of
the ATM kinase. This was not investigated further.
Selective knock-down of p53 reduces Cisplatin-induced
p21Waf1/Cip1 and Caspase 9 activation. It has previously been
shown that the apoptotic response of chemoresistant ovarian
cancer cells is significantly enhanced following reconstitution of
p53 (21). We have now investigated whether Cisplatin-induced
apoptosis and cell cycle arrest are both dependent on p53. Com-
paring p53 siRNA transfected A2780WT cells with scramble
siRNA transfected cells we find in two independent experiments
that p53 silencing reduces the increase in p53 and p21Waf1/Cip1
protein expression and Caspase 9 activity following 24 h exposure
to Cisplatin (10 M) from 56- to 4-fold (p53), 24- to 12-fold
(p21Waf1/Cip1), and 29- to 4-fold (Caspase 9). Similarly, we find in
4 experiments that p53 silencing in A549 cells reduces pp53 and
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Fig. 7. The Cisplatin induced phenotype of A2780CisR is reversible. Continued Cisplatin treatment of A2780CisR was stopped by omission of Cisplatin from
the growth medium, and cellular characteristics (taurine influx, swelling induced taurine efflux, and response to Cisplatin treatment) in the progressing cell line,
designated A2780Rev, were determined 3 and 6 wk (3w/6w) after redraw of Cisplatin. A: cellular taurine influx (nmol·g protein1·min1) was determined under
isotonic conditions by tracer technique in A2780WT, resistant cells (CisR), and reversing (A2780 Rev) cells. Taurine influx (nmol·g protein1·min1) was
determined from the slope of time traces. Values for A2780CisR and A2780Rev cells (gray bars) are given relative to A2780WT cells (open bars) and represent
means of 3 sets of experiments. *Significantly increased compared with WT cells. B: fractional rate constant (min1) for taurine release was determined and
plotted vs. time (min) under isosmotic and hyposmotic conditions. The maximal rate constant for taurine release was determined 6 min after hyposmotic exposure.
Data represent the mean maximal rate constants determined from 3 sets of experiments 	 SE. *Significantly reduced compared with control (Student’s t-test).
C–E: whole cell protein lysates for Western blot analysis were obtained from A2780WT, A2780CisR, and A2780Rev (after 3 and 6 wk) cells exposed to 10 M
Cisplatin for 24 h. Protein expression of LRRC8A, p53, p21, Noxa, Caspase-9, and Bax was determined using specific antibodies (see EXPERIMENTAL
PROCEDURES). 
-Actin or Histone 3 were used as loading controls. C: representative Western blot. D: LRRC8A protein expression relative to 
-actin in
A2780WT, A2780CisR, and A2780Rev (open bars) control cells and following 24 h Cisplatin exposure (black bars). Data represent 3–7 individual sets of
experiments, where ratios are given relative to the untreated WT cells 	 SE. * and #: Expression is significantly increased in Cisplatin-treated cell compared
with control cells and significantly reduced in Cisplatin-treated A2780CisR cells compared with Cisplatin-treated A2780WT cells, respectively (ANOVA, Fisher
LSD method); § indicates expression following cisplatin exposure is significantly increased in A2780 Rev compared with CisR (Student’s t-test). E: graph
represents the relative effect of Cisplatin (Cisplatin-treated/respective untreated control) on p53, p21, cleaved Caspase-9, and Noxa protein expression in
A2780WT, A2780CisR, and A2780Rev cells. Data represent mean of 3–7 individual experiments 	 SE. * and #: Expression is significantly increased in
Cisplatin-treated cell compared with control cells and significantly reduced in Cisplatin-treated A2780CisR cells compared with Cisplatin-treated A2780WT
cells, respectively (ANOVA, Fisher LSD method). § indicates expression following cisplatin exposure is significantly increased in A2780 Rev compared with
CisR (Student’s t-test).
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p21Waf1/Cip1 protein expression and Caspase 9 activity following
Cisplatin exposure, significantly from 67 	 15- to 13 	 2-fold
(pp53), 5	 1- to 1.7	 0.4-fold (p21Waf1/Cip1), and 7.0	 1.6- to
2.9 	 0.5-fold (Caspase 9) (Fig. 11). Hence, Cisplatin-induced
cell cycle arrest and apoptosis in wild-type A2780 and A549 cells
are p53 dependent.
DISCUSSION
Development of drug resistance is a continuing issue in
chemotherapeutic treatment. As indicated in the introduction,
the mechanism of platinum (II) resistance involves direct
changes in drug transport systems resulting in a reduced
intracellular drug accumulation, an enhanced drug detoxifica-
tion and damage tolerance, as well as changes in the apoptotic
signal transduction pathways (12, 24, 25, 32, 46). During the
past 15 years, it has however turned out that a hallmark in
apoptosis is isosmotic cell shrinkage, a process that is termed
apoptotic volume decrease (AVD) (29, 37).
The involvement of ion channels and transporters has been
associated with cancer progression and development of che-
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was determined and plotted vs. time (min). Data represent the mean of 11 sets of experiments. D: bar graph represents the maximal rate constant for taurine release
in A549WT, CisR5 and CisR10 determined 6 min after hyposmotic exposure (see A). Values are given relative to A549WT control and represent the mean of
11 (CisR5) and 5 (CisR10) sets of experiments 	 SE. *Significantly reduced compared with A549WT cells (Student’s t-test). E: quantification of whole cell
LRRC8A protein levels in A549WT, CisR5, and CisR10 cells determined by Western blot analysis using a monoclonal antibody against human LRRC8A. The
LRRC8A expression levels were normalized to 
-actin and the ratio given relative to A549WT. Data represent 5 (CisR5) and 10 (CisR10) sets of experiments
	 SE. *Significantly increased compared with A549WT cells (Student’s t-test). F: effect of LRRC8A knock-down on cell viability after Cisplatin treatment was
determined by MTT (see EXPERIMENTAL PROCEDURES). A549WT and CisR10 were transfected with either scramble or LRRC8A siRNA; following 1 day
transfection, half of the cells were treated with 10 M Cisplatin and left for another 48 h before measuring cell viability. Data represent 5 individual sets of
experiments 	 SE. * and #: Significantly decreased by Cisplatin compared with the respective control and significantly increased compared with Cisplatin
treatment in scramble siRNA transfected cells, respectively (ANOVA, Fisher LSD method).
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motherapeutic resistance for a long time. Back in 1992,
Gollapudi and coworkers (13) recognized an abnormal chloride
conductance in a multidrug-resistant human promyelogenous
HL60/AR leukemia cell line. The baseline Cl currents (100
mV) were consistently lower in HL60/AR compared with the
drug-sensitive HL60 parental cells. Furthermore, blocking Cl
channel activity in drug-sensitive HL60 cells with DIDS re-
sulted in deceased intracellular accumulation of the chemother-
apeutic drug daunorubicin and increased drug resistance, thus
pointing to the role of VRAC/VSOAC in development of
MDR.
In multidrug-resistant Ehrlich ascites tumor cells (MDR-
EATC), it has likewise been demonstrated that acquired drug
resistance involves a reduced activity of VRAC/VSOAC me-
diating the volume-sensitive Cl currents and efflux of amino
acids, e.g., taurine (37, 38). Administration of the pharmaco-
logical VRAC/VSOAC inhibitors, e.g., DIDS/NS3728 and the
TASK-2 cation channel blocker clofilium, have been shown to
reduce Cisplatin-induced cell shrinkage (AVD1) as well as
both Cisplatin- and anoxia-induced Caspase-3 activation in
drug-sensitive EATC-WT and A549WT (19, 37). In accor-
dance, we find that both VRAC/VSOAC blockage (NS3728
and DIDS) and transient knock-down of LRRC8A reduces the
Cisplatin-induced Caspase-3 activation and increases cell via-
bility in A2780WT to the same level as observed in
A2780CisR (Figs. 5 and 6).
As described previously, one of the major players in Cispla-
tin-induced apoptosis is the transcription factor p53. We find
that p53 siRNA transfection reduces Cisplatin-induced
Caspase-9 activation indicating that Cisplatin-induced apopto-
sis in both WT A2780 and A549 cells is p53-dependent.
Genome sequencing has revealed that over 50% of all human
malignancies exhibit p53 point mutations located in the DBD
region (35). Many of these mutations lead to its miss-folding,
decreased DNA binding capability, and even a gain-of-func-
tion of p53. In many other tumor cells p53, although it was
intact, was found to be inactive due to an enhanced degradation
and less activation. Acquired p53 inactivation or gain-of-
functions mutations are often associated with aggressive tumor
growth, development of chemotherapeutic resistance, and poor
survival prognosis (35). Compton and coworkers (7) have in
addition demonstrated that mitochondrial dysfunction seems to
protect cells from IR-induced cell death by repression of p53
activity. Recent studies clearly identify that acute hyperos-
motic stress leads to a biphasic stabilization and activation of
the transcription factor p53 in mouse NIH3T3 fibroblasts,
supposedly through Ser-15 phosphorylation by the serine/
threonine kinase ATM and the p38 MAP kinase (27). This
could indicate that LRRC8A is a mitochondrial protein, i.e.,
that lack of LRRC8A in the mitochondrial membrane leads to
mitochondrial dysfunction and repression of p53 activity.
LRRC8A is highly expressed in the plasma membrane (50) and
we therefore assume that cell shrinkage regulates p53 either
independently of the mitochondria or that shift in cell volume
contributes to mitochondrial dysfunction and hence p53 regu-
lation. In our studies, we clearly demonstrate that the VRAC/
VSOAC compound LRRC8A is essential for Cisplatin-induced
increase in p53, MDM2, and p21Waf1/Cip1 protein level as well
as Caspase-9 and -3 activation in both human ovarian A2780
and alveolar A549 cells. In contrast, LRRC8A inhibition had
no effect on hyperosmotic stress-induced Caspase-3 activity
and only a slight effect on TNF-induced Caspase-3 activation
in A2780, thus indicating that LRRC8A acts upstream to
shrinkage-induced and to TNF-induced apoptosis. We fur-
thermore find that transient expression of LRRC8A in
A2780CisR reestablishes the sensitivity toward Cisplatin (Fig.
6) and that cessation of a prolonged Cisplatin treatment, which
is used to maintain resistance in vitro, reverses the Cisplatin-
resistant phenotype and restore Cisplatin sensitivity. This con-
firms that the acquired Cisplatin resistance in A2780 cells is a
reversible condition. In drug-sensitive human K562 erythro-
leukemia cells and RK562 cells, which are doxorubicin resis-
tant and express P-glycoprotein and multidrug resistance pro-
teins (MDR1 and MRP1), Xu and colleagues (54) have re-
ported that administration of the board-spectrum anion-channel
blocker 5-nitro-2-(3-phenylpropylamino)benzoic acid (NPPB)
significantly blocks Cisplatin-induced activity and apoptosis in
both K562 and RK562 cells. Moreover, they found that NPPB
reduced the Cisplatin-induced protein expression of Bax/Bcl2,
cytochrome c and Caspase-3, thus supporting that LRRC8A-
mediated VRAC/VSOAC channel activity is important for
Cisplatin cytotoxicity and the intrinsic apoptotic pathway. A
schematic representation of the intrinsic apoptotic pathways
and the involvement of LRRC8A is given in Fig. 12. It is seen
that LRRC8A is essential for the AVD response which is an
initial step in the intrinsic pathway. Xu and colleagues (54)
also show that Cisplatin treatment reduces the mRNA accu-
mulation of cyclin D1 and the chloride channel 3 (ClC-3) in
both K562 and RK562 cells in a way avoided by cotreatment
with NPPB. The same group (47) later reported that ClC-3 is
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Fig. 9. LRRC8A expression in the plasma membrane of wild-type and
cisplatin-resistant A549 cells. Proteins exposed to the extracellular compart-
ment in A549WT and A549CisR10 cells were biotinylated, cells lysed, and
biotinylated proteins extracted and identified by Western blot as indicated in
EXPERIMENTAL PROCEDURES. A: representative blots where histone (H3) was
used to verify the absence of intact cells in the preparation and Na/K-
ATPase was used as loading control. B: protein ratio of LRRC8A/Na/K-
ATPase was calculated and given relative to the ratio in A549WT cells. Values
are mean of 3 sets of separate experiments. *Significantly reduced compared
with A549WT (Student’s t-test).
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an anti-apoptotic channel, as selective knock-down of ClC-3
expression caused inhibition of Akt and autophagy, and en-
hanced Cisplatin toxicity in human malignant U251 glioma cell
line. Thus not all anion channels are considered to be proapo-
ptotic like VRAC/VSOAC.
We have previously demonstrated that acute exposure of
Cisplatin-sensitive A2780 cells to 5 and 10 M Cisplatin for
18 h results in a marked increase in LRRC8A protein content,
whereas the same treatment had no effect on the LRRC8A
protein expression in A2780CisR (44). Similar to this, studies
by Planells-Cases and coworkers (36) indicate that Cisplatin-
induced taurine release is abolished in LRRC8A knock-out
HEK cells, and they define LRRC8A and LRRC8D as essential
for both swelling-induced taurine release as well as develop-
ment of drug resistance. As indicated in the Introduction,
sequence analysis revealed that the LRRC8 family are consid-
ered to originate from a common ancestor and to be closely
related to pannexins. Pannexins, like the LRRC8 membrane-
spanning proteins, form hexameric channels and are known to
be involved in leakage of Ca2 from the ER and ATP-
dependent cell death (1). As an example, Pannexin 1 channels
mediate “find-me” signals (e.g., ATP release) and increase
membrane permeability during Fas-receptor stimulated apo-
ptosis (6). The pannexin family is structurally related to con-
nexins, which also form hexameric complexes known as con-
nexons or connexin hemichannels. These comprise gap junc-
tions that connect the cytosol of neighboring cells, thus
allowing bidirectional flow of ions and signaling molecules
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Fig. 10. Selective knock-down of LRRC8A
abolishes Cisplatin-induced p53, MDM2, and
p21Waf1/Cip1 expression and reduces Caspase-9
cleavage in wild-type A549 cells. Western blot
analysis of whole cell protein lysates obtained
from A549WT, A549CisR10 cells and
A549WT cells treated with scramble or
LRRC8A siRNA exposed to Cisplatin for 24 h.
Protein expression of LRRC8A, p53, p-p53
(Ser15), p21, MDM2, p-MDM2 (Ser166),
Noxa, Caspase-9 and Bax, as well as ATM and
p-ATM (Ser1981) was determined using spe-
cific antibodies (see EXPERIMENTAL PROCE-
DURES) and 
-actin, histone-3, or -tubulin
served as loading controls (only one is shown).
A and B: representative Western blots. C: p53,
pp53, p21, Noxa, p-ATM, and MDM2 protein
expression relative to their loading controls in
A549WT and A549CisR10 (open bars) and
following 24 h Cisplatin exposure (black bars).
Data represent 3 to 6 individual sets of exper-
iments where ratios are given relative to the
untreated WT cells 	 SE. * and #: Expression
is significantly increased in Cisplatin-treated
cells compared with respective control cells
and significantly reduced in Cisplatin-treated
A549CisR10 cells compared with Cisplatin-
treated A549WT cells, respectively (ANOVA,
Fisher LSD method). D: relative protein ex-
pression of p53, pp53, p21, Noca, cleaved
Caspase-9, and MDM2 in A549WT cell treated
with either scramble or LRRC8A siRNA alone
(open bars) or in combination with 10 M
Cisplatin (black bars) for 24 h. Data represent
3–6 individual sets of experiments where ratios
are given relative to the untreated WT cells 	
SE. * and #: Expression is significantly in-
creased by Cisplatin cell compared with respec-
tive control cells and significantly reduced in
Cisplatin-treated LRRC8A siRNA cells com-
pared with Scramble siRNA cells, respectively
(ANOVA, Fisher LSD method).
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such as amino acids and nucleotides (2). Interestingly, like for
LRRC8A, connexin 43 (Cx43) protein expressions are report
to be downregulated in Cisplatin-resistant lung A549/DDP
cancer cells compared with Cisplatin-sensitive A549 cells (56).
In addition, overexpression of Cx43 enhanced Cisplatin cyto-
toxicity in mesothelioma H28 cells (41). The A549/CDDP
cells were found to acquire an epithelial-mesenchymal transi-
tion (EMT) phenotype, with morphological changes including
acquirement of a spindle-like fibroblastic phenotype, down-
regulation of E-cadherin, upregulation of mesenchymal mark-
ers (e.g., vimentin, Snail and Slug), and increased capability of
migration and invasion (56). Yu and coworkers (56) found that
overexpression of Cx43 reversed EMT and Cisplatin resistance
in the A549/CDDP cells. Mesenchymal integrins are often
highly overexpressed in tumor cells (9), and we have previ-
ously suggested that the Cisplatin-resistant phenotype in Eh-
rlich ascites Lettré cells is acquired through changes in mem-
bers of the integrin family, involving upregulation of integrins
often seen in mesenchymal cells (43). Inhibition of Cx43 with
the gap-junction inhibitor GA leads to enhanced drug resis-
tance in a resistant version of the A2780 cells (ACRP) (31).
Paradoxically, Li and coworkers (31) also find that the protein
expression of Cx43 is markedly upregulated in ACRP com-
pared with A2780. In our Cisplatin-resistant A549 cells, we
find that even though the total LRRC8A protein expression is
elevated compared with A549WT, the amount of LRRC8A in
their plasma membrane is significantly reduced which could
explain the concomitant 50% reduction in VRAC/VSOAC
activity. This indicates that changes in the overall protein
contents of certain genes do not necessarily equalize to the
same alteration in activity.
In conclusion, we have shown that the VRAC/VSOAC
component LRRC8A is an essential regulator of Cisplatin-
induced p53 protein activity and its downstream signaling
involving increased expression of p21Waf1/Cip1 and MDM2, as
well as activation of Caspase-9 and -3. Our data clearly
illustrate that downregulation/reduced translocation to the
plasma membrane and activation of LRRC8A contribute to
development of resistance against Cisplatin-induced apoptosis
in ovarian and lung carcinoma cells. Activation of LRRC8A
containing channels is upstream to apoptotic volume decrease
as hypertonic cell shrinkage induces apoptosis independent of
the presence of LRRC8A.
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